-Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two presentations highlighting the potential of Advaxis vectors to generate T cell responses to a...
ArQule, Inc.’s ARQL, -1.67% partner, Basilea Pharmaceutica Ltd. (six:BSLN), announced today that it entered into a collaboration with Roche (six:RO)(six:ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor,...
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Phase 1 single-ascending...
The WVU Cancer Institute is enrolling patients in an innovative clinical trial to treat ovarian cancer. Valerie Galvan Turner, M.D., gynecologic oncologist at the WVU Cancer Institute, will help lead the trial to evaluate the efficacy of varying dosages and...
Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in GRAVITAS-309, a pivotal Phase 3 trial for the first-line treatment of patients with chronic graft-versus-host disease (GVHD). The trial will evaluate the efficacy and safety of...
Email
Text